Cancer immunotherapy in patients with brain metastases

Salvatore Caponnetto; Arianna Draghi; Troels Holz Borch; Marianna Nuti; Enrico Cortesi; Inge Marie Svane; Marco Donia

doi:10.1007/s00262-018-2146-8

Cancer immunotherapy in patients with brain metastases

Salvatore Caponnetto, Arianna Draghi, Troels Holz Borch, Marianna Nuti, Enrico Cortesi, Inge Marie Svane^*, Marco Donia

^*Corresponding author af dette arbejde

Institut for Klinisk Medicin

7 Citationer (Scopus)

Abstract

The exclusion of “real-world” patients from registration clinical trials of cancer immunotherapy represents a significant emerging issue. For instance, a large fraction of cancer patients develops brain metastases during the course of the disease, but results from large prospective clinical trials investigating this considerable proportion of the cancer patient population are currently lacking. To provide a useful tool for the clinician in a “real-world” setting, we have reviewed the available literature regarding the safety and efficacy of immune check-point inhibitors in patients with cancer metastatic to the brain. Overall, these data provide encouraging evidence that these therapeutic agents can induce intracranial objective responses, particularly in patients with asymptomatic and previously untreated brain metastases. Larger prospective studies are needed to confirm these initial results.

Originalsprog	Engelsk
Tidsskrift	Cancer Immunology, Immunotherapy
Vol/bind	67
Udgave nummer	5
Sider (fra-til)	703-711
Antal sider	9
ISSN	0340-7004
DOI	https://doi.org/10.1007/s00262-018-2146-8
Status	Udgivet - 2018

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1007/s00262-018-2146-8

Citationsformater

@article{3a29de0f20ea4f5f8fecbdeeb7400beb,

title = "Cancer immunotherapy in patients with brain metastases",

abstract = "The exclusion of “real-world” patients from registration clinical trials of cancer immunotherapy represents a significant emerging issue. For instance, a large fraction of cancer patients develops brain metastases during the course of the disease, but results from large prospective clinical trials investigating this considerable proportion of the cancer patient population are currently lacking. To provide a useful tool for the clinician in a “real-world” setting, we have reviewed the available literature regarding the safety and efficacy of immune check-point inhibitors in patients with cancer metastatic to the brain. Overall, these data provide encouraging evidence that these therapeutic agents can induce intracranial objective responses, particularly in patients with asymptomatic and previously untreated brain metastases. Larger prospective studies are needed to confirm these initial results.",

keywords = "Brain metastases, Cancer immunotherapy, Check-point inhibitors, Ipilimumab, Nivolumab, Pembrolizumab",

author = "Salvatore Caponnetto and Arianna Draghi and Borch, {Troels Holz} and Marianna Nuti and Enrico Cortesi and Svane, {Inge Marie} and Marco Donia",

year = "2018",

doi = "10.1007/s00262-018-2146-8",

language = "English",

volume = "67",

pages = "703--711",

journal = "Cancer Immunology, Immunotherapy",

issn = "0340-7004",

publisher = "Springer",

number = "5",

}

TY - JOUR

T1 - Cancer immunotherapy in patients with brain metastases

AU - Caponnetto, Salvatore

AU - Draghi, Arianna

AU - Borch, Troels Holz

AU - Nuti, Marianna

AU - Cortesi, Enrico

AU - Svane, Inge Marie

AU - Donia, Marco

PY - 2018

Y1 - 2018

N2 - The exclusion of “real-world” patients from registration clinical trials of cancer immunotherapy represents a significant emerging issue. For instance, a large fraction of cancer patients develops brain metastases during the course of the disease, but results from large prospective clinical trials investigating this considerable proportion of the cancer patient population are currently lacking. To provide a useful tool for the clinician in a “real-world” setting, we have reviewed the available literature regarding the safety and efficacy of immune check-point inhibitors in patients with cancer metastatic to the brain. Overall, these data provide encouraging evidence that these therapeutic agents can induce intracranial objective responses, particularly in patients with asymptomatic and previously untreated brain metastases. Larger prospective studies are needed to confirm these initial results.

AB - The exclusion of “real-world” patients from registration clinical trials of cancer immunotherapy represents a significant emerging issue. For instance, a large fraction of cancer patients develops brain metastases during the course of the disease, but results from large prospective clinical trials investigating this considerable proportion of the cancer patient population are currently lacking. To provide a useful tool for the clinician in a “real-world” setting, we have reviewed the available literature regarding the safety and efficacy of immune check-point inhibitors in patients with cancer metastatic to the brain. Overall, these data provide encouraging evidence that these therapeutic agents can induce intracranial objective responses, particularly in patients with asymptomatic and previously untreated brain metastases. Larger prospective studies are needed to confirm these initial results.

KW - Brain metastases

KW - Cancer immunotherapy

KW - Check-point inhibitors

KW - Ipilimumab

KW - Nivolumab

KW - Pembrolizumab

U2 - 10.1007/s00262-018-2146-8

DO - 10.1007/s00262-018-2146-8

M3 - Review

C2 - 29520474

AN - SCOPUS:85043374117

SN - 0340-7004

VL - 67

SP - 703

EP - 711

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

IS - 5

ER -

Cancer immunotherapy in patients with brain metastases

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater